Affymetrix, Inc. 

(Public, NASDAQ:AFFX)   Watch this stock   
Find more results for AFFX)
Feb 3, 2010
Q4 2009 Earnings Conference Call - Webcast
Feb 3, 2010
Q4 2009 Earnings Release
Jan 14, 2010
JPMorgan Healthcare Conference
Dec 1, 2009
Nasdaq OMX Investor Conference
More events from AOL Finance »    

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin 3.15% -7.31%
Operating margin 2.77% -4.80%
EBITD margin - -
Return on average assets 1.80% -3.56%
Return on average equity 3.82% -7.95%
Employees 1,128 -

Address

3420 Central Expressway
Santa Clara, CA 95051
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Transcripts - SeekingAlpha

Affymetrix, Inc. discussions

  View all discussions »

Description

Affymetrix, Inc. is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. The markets for the Company’s products include all aspects of molecular biology research in the life sciences, including basic human disease research, genetic analysis, pharmaceutical drug discovery and development, pharmacogenomics (research relating to how a person's genes affect the body's response to drug treatments), toxicogenomics and molecular diagnostics. Its integrated GeneChip microarray platform includes disposable deoxyribonucleic acid (DNA) probe arrays (chips) consisting of nucleic acid sequences set out in an ordered, high-density pattern, certain reagents for use with the probe arrays, a scanner and other instruments used to process the probe arrays, and software to analyze and manage genomic or genetic information obtained from the probe arrays.

Officers and directors

Stephen P.A. Fodor Ph.D.
Executive Chairman of the Board
Age: 55
Bio & Compensation - Reuters
Kevin M. King
President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
John C. Batty
Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation - Reuters
John F. Runkel Jr.
Executive Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation - Reuters
John D. Diekman Ph.D.
Director
Age: 66
Bio & Compensation - Reuters
Paul Berg Ph.D.
Director
Age: 82
Bio & Compensation - Reuters
John A. Young
Director
Age: 77
Bio & Compensation - Reuters
Robert H. Trice Ph.D.
Director
Age: 62
Bio & Compensation - Reuters
Robert P. Wayman
Director
Age: 64
Bio & Compensation - Reuters